Abstract P044 – Table 1. Discontinuations of DTG + 3TC in women and men with HIV.
Maggiolo EACS 2017 (N = 203)
Cause of discontinuation, n (%)	Cause of discontinuation, n (%)	Men (n = 153)
Discontinuationsa	5 (10)b	7 (5)
Muscle aches	3 (6)	0
Headache	1 (2)	0
CNS symptoms	1 (2)	1 (<1)
Asthenia	1 (2)	0
Lost to follow‐up	1 (2)	1 (<1)
Cancer‐related metastasis	1 (2)	1 (<1)
Voluntary treatment interruption	0	2 (1)
Elevated liver function tests	0	1 (<1)
Alcohol‐induced cirrhosis	0	1 (<1)
Stephenson BHIVA 2020 (N = 100)
Cause of discontinuation, n (%)	Women (n = 26)	Men (n = 74)
Discontinuations	4 (15)	2 (3)
CNS intolerance	1 (4)	0
Gastrointestinal intolerance	1 (4)	0
Virologic escape	1 (4)c	1 (1)d
Pregnancy	1 (4)	0
Arthralgia	0	1 (1)

3TC, lamivudine; BHIVA, British HIV Association; CNS, central nervous system; DTG, dolutegravir; EACS, European AIDS Clinical Society.

^aAll participants had viral load <50 copies/mL at last visit;

^btwo women had multiple causes of discontinuation: one with muscle aches and asthenia and one with headache, CNS symptoms, and muscle aches;

^cviral load was 15 135 copies/mL before discontinuation. Virologic suppression achieved on bictegravir/emtricitabine/tenofovir alafenamide;

^dviral load was 124 copies/mL before discontinuation. Virologic suppression achieved on DTG + tenofovir disoproxil fumarate/emtricitabine.